NCT04066881Befejeződött2. fázis
A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure Prophylaxis
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. jan. 22.
Rövid összefoglaló (regiszter, angolul)
This international, multi-centre, double-blind vaccine study is a three-arm prospective 1:1:1 randomisation comparing each of two experimental combination vaccine regimens i.e. DNA/AIDSVAX (weeks 0,4,24,48) and DNA/CN54gp140 (weeks 0,4) + MVA/CN54gp140 (weeks 24,48) with placebo control. There will be a concurrent open-label 1:1 randomisation to compare daily TAF/FTC (week 0-26) to daily TDF/FTC (weeks 0-26) as pre-exposure prophylaxis. The study aims to randomise up to 1668 eligible adults (18-40 years) through collaborating clinical research centres in 4 countries (Mozambique; South Africa; Tanzania; and Uganda). Each participant will be followed for a minimum of 74 weeks after enrolment. The trial is designed to detect a reduction in HIV incidence that has public health relevance sufficient to justify implementation of the combination vaccine regimen. In light of the high level of effectiveness demonstrated in the PrEP trials (up to 86% reduction in HIV), this trial is powered to detect a protective vaccine efficacy of 70% at the final analysis. The PrEP component will determine whether the effectiveness of TAF/FTC is unacceptably lower than the effectiveness of TDF/FTC.
- Állapot (regiszter)
- Befejeződött
- Fázis (regiszter)
- 2. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 1512 (tényleges)
- Első benyújtás
- 2019. aug. 8.
- Kezdés
- 2020. dec. 15.
- Elsődleges befejezés
- 2024. dec. 31.
- Fő szponzor
- MRC/UVRI and LSHTM Uganda Research Unit
- Betegségek
- HIV-fertőzés
- NCT-szám
- NCT04066881
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 2. fázis
- Bevont résztvevők: 1512
- 2020. dec. 15. és az elsődleges befejezés (2024. dec. 31.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Participating in another biomedical research study or in receipt of a live vaccine within 30 days prior to randomisation
- Participation in a previous HIV vaccine or HIV immunotherapy trial
- Receiving blood products or immunoglobulins within 12 weeks of screening
Más betegség
- HIV infection or indeterminate HIV result at screening or enrolment
- Hepatitis B surface antigen positive
- Known hypersensitivity to any component of the vaccine formulations used in this trial or history of severe or multiple allergies to vaccines, drugs or pharmaceutical agents
- Presence of a systemic disease at the time of randomisation or history of chronic illness that in the opinion of the investigator may compromise the participant's safety, preclude vaccination or compromise an immune response to vaccine
Laborértékek
- If female, currently pregnant (evidence from positive serum or urine pregnancy test), or lactating
- Abnormalities in routine laboratory parameters (Hb, creatinine, AST/ALT, alkaline phosphatase, total Bilirubin and glucose) of Grade 2 and above using the DAIDS toxicity table, version 2.1 July 2017 or estimated glomerular filtration rate less than 50ml/min
Kiket keres a vizsgálat
- HIV uninfected adults aged between 18 and 40 years old on the day of screening
- Willing and able to provide informed consent prior to participation
- Willing and able to comply with the visit schedule and provide blood, urine and other samples at the required time points
- Home address accessible for visiting and intending to remain within the recruitment area for at least 82 weeks from screening
- Likely to be at risk from exposure to HIV during follow up
- Willing to undergo HIV testing, receive HIV test results and risk reduction counselling which includes promotion of PrEP and condoms
- If female, of child-bearing age and not sterilised, willing to use a highly effective method of contraception from screening until 18 weeks after the last injection
- If male and not sterilised, willing to avoid impregnating female partners from screening until 18 weeks after the last injection
Életkor a regiszterben: 18 év – 40 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| MRC/UVRI and LSHTM Uganda Research Unit | Entebbe | Uganda | Ismeretlen állapot |
Kapcsolódó publikációk
- Nurse counselors' experiences of recruitment and retention of female sex workers in a HIV vaccine trial: a qualitative study from urban Tanzania.Trials · 2026 · PMID 42410635
- A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.J Acquir Immune Defic Syndr · 2026 · PMID 41650395
- Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study.Trials · 2026 · PMID 42141483
- The experience of trial participation disclosure among sex workers in a phase IIb HIV vaccine trial: A qualitative study in urban Tanzania.PLOS Glob Public Health · 2025 · PMID 41259346
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.